PRICE T ROWE ASSOCIATES INC /MD/ - KARYOPHARM THERAPEUTICS INC ownership

KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 155 filers reported holding KARYOPHARM THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 1.24 and the average weighting 0.1%.

Quarter-by-quarter ownership
PRICE T ROWE ASSOCIATES INC /MD/ ownership history of KARYOPHARM THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$117
-4.1%
87,113
+27.9%
0.00%
Q2 2023$122
-48.3%
68,108
+12.6%
0.00%
Q1 2023$236
+19.8%
60,466
+4.3%
0.00%
Q4 2022$197
-99.9%
57,955
+10.3%
0.00%
Q3 2022$287,000
+68.8%
52,532
+39.5%
0.00%
Q2 2022$170,000
-12.4%
37,670
+43.2%
0.00%
Q1 2022$194,000
+48.1%
26,298
+28.8%
0.00%
Q4 2021$131,000
-49.8%
20,412
-54.6%
0.00%
Q3 2021$261,000
-93.7%
44,912
-88.7%
0.00%
Q2 2021$4,119,000
-20.6%
399,099
-19.0%
0.00%
-100.0%
Q1 2021$5,186,000
-77.0%
492,955
-66.2%
0.00%
-50.0%
Q4 2020$22,553,000
+7.5%
1,456,901
+1.4%
0.00%0.0%
Q3 2020$20,980,000
-43.5%
1,437,011
-26.7%
0.00%
-60.0%
Q2 2020$37,152,000
+38.7%
1,961,580
+40.6%
0.01%
+25.0%
Q1 2020$26,793,000
+723.4%
1,394,739
+721.6%
0.00%
Q4 2019$3,254,000
+2026.8%
169,759
+1121.7%
0.00%
Q3 2017$153,000
+21.4%
13,8950.0%0.00%
Q2 2017$126,000
-29.2%
13,895
+0.2%
0.00%
Q1 2017$178,000
+36.9%
13,8740.0%0.00%
Q4 2016$130,000
-3.7%
13,8740.0%0.00%
Q3 2016$135,000
+45.2%
13,8740.0%0.00%
Q2 2016$93,000
-25.0%
13,874
-0.2%
0.00%
Q1 2016$124,000
-32.6%
13,9000.0%0.00%
Q4 2015$184,00013,9000.00%
Other shareholders
KARYOPHARM THERAPEUTICS INC shareholders Q4 2022
NameSharesValueWeighting ↓
Consonance Capital Management LP 7,180,700$137,941,00010.27%
Palo Alto Investors LP 4,299,901$82,601,0006.92%
Fairmount Funds Management LLC 562,351$10,803,0006.55%
Avoro Capital Advisors LLC 7,000,000$134,470,0004.54%
Pinz Capital Management, LP 8,820$1,694,0004.44%
Birchview Capital, LP 148,000$2,843,0002.52%
Elk Creek Partners, LLC 699,951$13,446,0002.31%
Parkman Healthcare Partners LLC 215,802$4,146,0001.92%
EAM Global Investors LLC 136,402$2,620,0001.53%
SPHERA FUNDS MANAGEMENT LTD. 550,000$10,566,0001.32%
View complete list of KARYOPHARM THERAPEUTICS INC shareholders